Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow?

被引:70
作者
dekemp, Robert A.
Yoshinaga, Keiichiro
Beanlands, Rob S. B.
机构
[1] Univ Ottawa, Inst Heart, Natl Cardiac PET Ctr, Ottawa, ON K1Y 4W7, Canada
[2] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 060, Japan
关键词
D O I
10.1016/j.nuclcard.2007.04.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Quantification of myocardial blood flow (MBF) and flow reserve has been used extensively with positron emission tomography (PET) to investigate the functional significance of coronary artery disease. Increasingly, flow quantification is being applied to investigations of microvascular dysfunction in early atherosclerosis and in nonatherosclerotic microvascular disease associated with primary and secondary cardiomyopathies. Fully three-dimensional (3D) acquisition is becoming the standard imaging mode on new equipment, bringing with it certain challenges for cardiac PET, but also the potential for MBF to be measured simultaneously with routine electrocardiography (ECG)-gated perfusion imaging. Existing 3D versus 2D comparative studies support the use of 3D cardiac PET for flow quantification, and these protocols can be translated to PET-CT, which offers a virtually noise-free attenuation correction. This technology combines the strengths of cardiac CT for evaluation of anatomy with cardiac PET for quantification of the hemodynamic impact on the myocardium. High throughput clinical imaging protocols are needed to evaluate the incremental diagnostic and prognostic value of this technology.
引用
收藏
页码:380 / 397
页数:18
相关论文
共 152 条
[1]   Optimization of a fully 3D single scatter simulation algorithm for 3D PET [J].
Accorsi, R ;
Adam, LE ;
Werner, ME ;
Karp, JS .
PHYSICS IN MEDICINE AND BIOLOGY, 2004, 49 (12) :2577-2598
[2]   Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists - A comparison of lismopril and losartan [J].
Akinboboye, OO ;
Chou, RL ;
Bergmann, SR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (04) :703-709
[3]  
BACHARACH SL, 1992, POSITRON EMISSION TO, P13
[4]   Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis [J].
Baller, D ;
Notohamiprodjo, G ;
Gleichmann, U ;
Holzinger, J ;
Weise, R ;
Lehmann, J .
CIRCULATION, 1999, 99 (22) :2871-2875
[5]   Reply [J].
Timothy M. Bateman ;
Gary V. Heller ;
S. James Cullom .
Journal of Nuclear Cardiology, 2006, 13 (4) :591-592
[6]   CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease - executive summary [J].
Beanlands, R. S. B. ;
Chow, B. J. W. ;
Dick, A. ;
Friedrich, M. G. ;
Gulenchyn, K. Y. ;
Kiess, M. ;
Leong-Poi, H. ;
Miller, R. M. ;
Nichol, G. ;
Freeman, M. ;
Bogaty, P. ;
Honos, G. ;
Hudon, G. ;
Wisenberg, G. ;
Van Berkom, J. ;
Williams, K. ;
Yoshinaga, K. ;
Graham, J. .
CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 (02) :107-119
[7]   Positron emission tomography and recovery following revascularization (PARR-1): The importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function [J].
Beanlands, RSB ;
Ruddy, TD ;
deKemp, RA ;
Iwanochko, RM ;
Coates, G ;
Freeman, M ;
Nahmias, C ;
Hendry, P ;
Burns, RJ ;
Lamy, A ;
Mickleborough, L ;
Kostuk, W ;
Fallen, E ;
Nichol, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (10) :1735-1743
[8]   Can nitrogen-13 ammonia kinetic modeling define myocardial viability independent of fluorine-18 fluorodeoxyglucose? [J].
Beanlands, RSB ;
deKemp, R ;
Scheffel, A ;
Nahmias, C ;
Garnett, ES ;
Coates, G ;
Johansen, HL ;
Fallen, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (03) :537-543
[9]  
BELLINA CR, 1990, J NUCL MED, V31, P1335
[10]   Effect of metoprolol on absolute myocardial blood flow in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy [J].
Bennett, SK ;
Smith, MF ;
Gottlieb, SS ;
Fisher, ML ;
Bacharach, SL ;
Dilsizian, V .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (12) :1431-1434